Neurocrine Biosciences Inc. (NBIX)
NBIX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/914475/000091447526000007/0000914475-26-000007-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NBIX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1996 |
| SEC CIK | 0000914475 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.9B |
| Net income | $478.6M |
| Operating income | $619.1M |
| Net margin | 16.7% |
| Operating margin | 21.6% |
| Revenue growth | +21.4% |
| Cash | $713.0M |
| Total assets | $4.6B |
| P/E (computed) | 35.0× |
| P/S (computed) | 5.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $641.5M cash; operating cash flow $266.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 101,218,643 (2026-10-26); 99,705,698 a year earlier; 98,251,923 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Diego, California, United States | PCAOB Form AP 2026-03-03 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $77.9M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $1.1B | $206.5M | $395.2M | $641.5M | No debt tags | $3.7B | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $959.0M | $144.4M | $136.4M | $332.4M | No debt tags | $3.4B | 10-Q 2026-07-31 |
| Q1 2026 2026-03-31 | $814.5M | $197.9M | $145.8M | $266.5M | No debt tags | $3.1B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $805.5M | $153.7M | $388.4M | $713.0M | No debt tags | $2.9B | 10-K 2026-02-11 |
| Q3 2025 2025-09-30 | $794.9M | $209.5M | $227.5M | $340.2M | No debt tags | $2.7B | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $687.5M | $107.5M | $102.0M | $264.0M | No debt tags | $2.5B | 10-Q 2026-07-31 |
| Q1 2025 2025-03-31 | $572.6M | $7.9M | $64.8M | $194.1M | No debt tags | $2.4B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $627.7M | $103.1M | $242.5M | $233.0M | $0 | $2.4B | 10-K 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-15 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.7% |
| 1 month | +23.9% |
| 3 months | +11.0% |
| Year to date | +18.0% |
| 1 year | +16.1% |
| From 52-week high | -9.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
| KYMR | Kymera Therapeutics Inc. | $125.85 | -1.35% | $10.7B |
| RGEN | Repligen Corporation | $162.78 | -2.99% | $10.4B |
| QGEN | Qiagen N.V. Common Shares | $49.81 | -0.16% | $10.3B |
| PCVX | Vaxcyte Inc. | $61.61 | -2.78% | $9.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier